Unichem Laboratories rose 2.91% to Rs 184 after the company said that US drug regulator's inspection at Roha concluded successfully without any FDA form 483.
The United States Food and Drug Administration (USFDA) conducted inspection at the company's active pharmaceutical ingredients (APIs) facility at Roha from 9 to 12 September 2019. The inspection was a post approval inspection and successfully concluded without any FDA form 483 issued.Meanwhile, the S&P BSE Sensex was down 41 points or 0.11% to 37,063.11.
On the BSE, 6083 shares were traded in the counter so far compared with average daily volumes of 6359 shares in the past one quarter. The stock hit a high of Rs 187 and a low of Rs 182.2 so far during the day.
The stock hit a 52-week high of Rs 227 on 30 Oct 2018. The stock hit a 52-week low of Rs 158.35 on 31 Jul 2019.
On a consolidated basis, Unichem Lab reported a net loss of Rs 6.19 crore in Q1 June 2019 over a net loss of Rs 20.46 crore in Q1 June 2019 over Q1 June 2018.
Unichem Laboratories is a pharmaceutical company addressing the needs of relevant and growing therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content